Aegis Critical Energy Defence Corp. (CSE: QESS) (OTCQB: QESSF) (FSE: JG6) ("Aegis") is pleased to congratulate Quantum eMotion Corp. (TSXV: QNC) (OTCQB: QNCCF) (FSE: 34Q0) on filing its Form 40-F ...

The applicants say the plant would generate enough electricity to supply about 78,018 local households annually. | ITV News ...

OSAKA, Japan & CAMBRIDGE, Mass. & NEWARK, Calif. Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the ...

The IRS has released Form 4547, allowing parents to register eligible children for Trump Accounts when filing 2025 tax ...

Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives ...

WENZHOU, China, Jan. 6, 2026 /PRNewswire/ -- Recently, VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, ...

(MENAFN- GlobeNewsWire - Nasdaq) LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant ...

LOR is the first drug candidate with disease-modifying potential for osteoarthritis submitted for approval, demonstrating statistically and clinically significant improvements in pain, function and ...

SAN DIEGO, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule ...

Takeda ( TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved ...